Related Experiment Video
Updated: Oct 13, 2025
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Overexpressed GNA13 induces temozolomide sensitization via down-regulating MGMT and p-RELA in glioma
Yan Liu1, Zepeng Du2, Zhennan Xu1
1Department of Neurosurgery, Shantou Central Hospital Shantou 515041, China.
Abstract:
Temozolomide (TMZ), one of the few effective drugs used during adjuvant therapy, could effectively prolong the overall survival (OS) of glioma patients. In our previous study, the mRNA level of G Protein Subunit Alpha 13 (GNA13) was found to be inversely correlated with OS and was therefore identified as a potential biomarker for the prognosis of glioma. Henceforth, this study aims to identify the molecular mechanism of GNA13 in enhancing TMZ sensitization through bioinformatic analyses of GSE80729 and GSE43452 and other experiments. In glioma, overexpression of GNA13 downregulated PRKACA, which is a subunit of PKA, hence reducing phosphorylated RELA and MGMT. Since p-RELA and MGMT were proven to be closely associated with TMZ resistance, we therefore investigated whether thetwo signaling pathways, "GNA13/PRKACA/p-RELA", and "GNA13/PRKACA/MGMT", were involved in the molecular mechanism of GNA13 in TMZ sensitization. Our conclusion was that, GNA13 overexpression in glioma cells were more sensitive in TMZ treatment.
Insights
Overexpressing G Protein Subunit Alpha 13 (GNA13) enhances glioma patient sensitivity to temozolomide (TMZ) therapy. This occurs by downregulating PRKACA, reducing p-RELA and MGMT, key factors in TMZ resistance.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Temozolomide (TMZ) is a key adjuvant therapy for glioma, prolonging overall survival (OS).
- G Protein Subunit Alpha 13 (GNA13) mRNA levels inversely correlate with OS in glioma, suggesting prognostic significance.
- Understanding GNA13's role in TMZ resistance is crucial for improving glioma treatment.
Purpose of the Study:
- To elucidate the molecular mechanism by which GNA13 enhances temozolomide (TMZ) sensitization in glioma.
- To investigate the involvement of the "GNA13/PRKACA/p-RELA" and "GNA13/PRKACA/MGMT" signaling pathways in GNA13-mediated TMZ sensitization.
Main Methods:
- Bioinformatic analyses of gene expression datasets (GSE80729, GSE43452).
- Experimental validation of GNA13's effect on PRKACA, phosphorylated RELA (p-RELA), and O6-methylguanine-DNA methyltransferase (MGMT) expression.
- Assessment of TMZ sensitivity in glioma cells with altered GNA13 expression.
Main Results:
- Overexpression of GNA13 in glioma leads to downregulation of PRKACA, a protein kinase A (PKA) subunit.
- Reduced PRKACA levels result in decreased phosphorylation of RELA (p-RELA) and MGMT expression.
- These molecular changes are associated with enhanced sensitivity of glioma cells to TMZ treatment.
Conclusions:
- GNA13 overexpression enhances TMZ sensitization in glioma by modulating the GNA13/PRKACA/p-RELA and GNA13/PRKACA/MGMT signaling pathways.
- GNA13 acts as a potential therapeutic target to overcome TMZ resistance in glioma.
- Targeting GNA13 could represent a novel strategy to improve treatment outcomes for glioma patients receiving adjuvant TMZ therapy.
